title: [Maternal and neonatal drug resistance].
abstract: The debatable article gives new evidence for the possibility, conditions, and resistance rate of the resistance to nevirapine, which results from its single use during labor for the prevention of vertical HIV transmission. The author analyzes the results of the 2009-2010 studies dealing with the use of high-sensitive methods for mutation detection, the impact of minor mutations on therapeutic effectiveness, and the evaluation of the effect of therapeutic support. She expressed the idea that it is expedient to test HIV for nevirapine resistance mutations in different periods after single administration of the drug as a prophylactic agent, the possible effects and algorithm of treatment if the above mutations are detected.
authors.forename: M R
authors.initials: MR
authors.lastname: Bobkova
mesh_terms: D019380:Anti-HIV Agents / Q000494:pharmacology* / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active; D002675:Child, Preschool; D024882:Drug Resistance, Viral / Q000187:drug effects / Q000235:genetics; D005260:Female; D015658:HIV Infections / Q000188:drug therapy / Q000517:prevention & control / Q000635:transmission / Q000821:virology; D015497:HIV-1 / Q000187:drug effects / Q000235:genetics*; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D018445:Infectious Disease Transmission, Vertical / Q000517:prevention & control; D009154:Mutation / Q000187:drug effects*; D019829:Nevirapine / Q000494:pharmacology* / Q000627:therapeutic use; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000517:prevention & control / Q000821:virology; D019562:Viral Load
chemical_list: D019380:Anti-HIV Agents; D019829:Nevirapine